The Institute of Cancer Research
Sutton, Surrey
Salary: £39,805 - £41,900. Commencement on the salary range is subject to comparables skills and experience. Reporting to: Dr Fiona Dziegiel (Scientific Project Manager) Duration ofContract: Fixed Term Contract until the 31-December 2027 in the first instance, with the potential to extend subject to funding Hours per week: 35 hours per week (Full Time) Closing Date: Sunday 29th March 2026 This role is eligible for ICR Sponsorship. If this is your first visa in the UK, support will be provided for costs associated with Visa application. If you are considering relocating to the UK, further information can be found here. Under the guidance of Dr Fiona Dziegiel , we are seeking to recruit a Scientific Writer to produce clear, accurate and engaging scientific content to showcase the innovative research of the Centres for Protein Degradation and Cancer Drug Discovery to enhance external visibility. About you The successful candidate must have: PhD in life sciences, health sciences, or related field Excellent writing skills with the ability to translate complex scientific concepts into clear and engaging content Experience writing manuscripts and social media content Excellent organisational skills, flexibility and the ability to manage changing priorities Ability to work independently and collaboratively The postholder will support the development, editing and management of scientific documents including manuscripts, reports, presentations and material for grant applications. They will coordinate data collection, maintain organised information systems, and manage online and social media content to strengthen the Centres' visibility. Working closely with scientists, project managers, and the professional services teams, the Scientific Writer will ensure timely, effective communication of research activities and key developments, helping to advance the Centres' missions to discover and develop innovative cancer therapeutics. Department Information The Centre for Protein Degradation The ICR established the Centre for Protein Degradation (CPD) in 2022 to accelerate targeted protein degradation-based drug discovery - an innovative approach utilising drug-induced degradation of harmful proteins via the cell's endogenous protein disposal system. Our aim is to discover novel molecular glue degraders and PROTACs for the treatment of the most challenging cancers. Based at the ICR's Centre for Cancer Drug Discovery, the CPD benefits from state-of-the-art drug discovery platforms - biology, medicinal and in silico chemistry, biophysics, structural biology, proteomics, bioinformatics, as well as strong cancer biology and clinical expertise within the wider ICR and the Royal Marsden Hospital. We also have established collaborations with biotechnology companies and the pharmaceutical industry. The Centre for Cancer Drug Discovery The Division of Cancer Therapeutics has an unrivalled track record at discovering novel cancer treatments for the personalised treatment of cancer. Within the Division, the Centre for Cancer Drug Discovery (CCDD) is a multidisciplinary 'bench to bedside' centre, comprising 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. We are one of the largest academic cancer drug discovery groups in the world and, together with our collaborators, have discovered 21 preclinical development candidates, 13 of which have been progressed to clinical evaluation, many with our partners in the ICR/Royal Marsden Drug Development Unit. Our drug abiraterone (Zytiga) has been approved in the US, Canada and Europe for late-stage prostate cancer. The CCDD's mission is to develop personalised medicines by translating information from the cancer genome and cancer biology into drugs for patient benefit. We implement innovative drug discovery technologies, discover novel mechanism-based drugs, and develop these as rapidly as possible from the laboratory through to hypothesis-testing early clinical trials. We publish our work extensively and have a large network of collaborations with academia, biotechnology companies, and the pharmaceutical industry. Our teams are dedicated to the discovery of small molecule drug candidates, and to the development of high-quality chemical probes to enable new cancer biology research. The Division of Cancer Therapeutics is based in state-of-the art laboratories in the Centre for Cancer Drug Discovery building, opened in 2020 on the ICR Sutton campus. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For further information, please contact Dr Fiona Dziegiel ( ) About The Institute of Cancer Research Why work for us? As a member of staff, you'll have exclusive access to a range of staff benefits . The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information. The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here. At the Institute of Cancer Research, we champion diversity as we believe it fuels innovation and drives impactful research. We welcome applicants from all walks of life, valuing diverse perspectives that enrich our work. Don't let a checklist of qualifications hold you back - if you're passionate about the role, we want to hear from you. Your unique experiences and backgrounds contribute to the richness of our team. We are committed to being an equal opportunity for all, regardless of ethnicity, gender, age, sexual orientation, disability, or any other dimension of diversity. Join us in creating an inclusive environment where everyone's voice is heard and valued.
Salary: £39,805 - £41,900. Commencement on the salary range is subject to comparables skills and experience. Reporting to: Dr Fiona Dziegiel (Scientific Project Manager) Duration ofContract: Fixed Term Contract until the 31-December 2027 in the first instance, with the potential to extend subject to funding Hours per week: 35 hours per week (Full Time) Closing Date: Sunday 29th March 2026 This role is eligible for ICR Sponsorship. If this is your first visa in the UK, support will be provided for costs associated with Visa application. If you are considering relocating to the UK, further information can be found here. Under the guidance of Dr Fiona Dziegiel , we are seeking to recruit a Scientific Writer to produce clear, accurate and engaging scientific content to showcase the innovative research of the Centres for Protein Degradation and Cancer Drug Discovery to enhance external visibility. About you The successful candidate must have: PhD in life sciences, health sciences, or related field Excellent writing skills with the ability to translate complex scientific concepts into clear and engaging content Experience writing manuscripts and social media content Excellent organisational skills, flexibility and the ability to manage changing priorities Ability to work independently and collaboratively The postholder will support the development, editing and management of scientific documents including manuscripts, reports, presentations and material for grant applications. They will coordinate data collection, maintain organised information systems, and manage online and social media content to strengthen the Centres' visibility. Working closely with scientists, project managers, and the professional services teams, the Scientific Writer will ensure timely, effective communication of research activities and key developments, helping to advance the Centres' missions to discover and develop innovative cancer therapeutics. Department Information The Centre for Protein Degradation The ICR established the Centre for Protein Degradation (CPD) in 2022 to accelerate targeted protein degradation-based drug discovery - an innovative approach utilising drug-induced degradation of harmful proteins via the cell's endogenous protein disposal system. Our aim is to discover novel molecular glue degraders and PROTACs for the treatment of the most challenging cancers. Based at the ICR's Centre for Cancer Drug Discovery, the CPD benefits from state-of-the-art drug discovery platforms - biology, medicinal and in silico chemistry, biophysics, structural biology, proteomics, bioinformatics, as well as strong cancer biology and clinical expertise within the wider ICR and the Royal Marsden Hospital. We also have established collaborations with biotechnology companies and the pharmaceutical industry. The Centre for Cancer Drug Discovery The Division of Cancer Therapeutics has an unrivalled track record at discovering novel cancer treatments for the personalised treatment of cancer. Within the Division, the Centre for Cancer Drug Discovery (CCDD) is a multidisciplinary 'bench to bedside' centre, comprising 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. We are one of the largest academic cancer drug discovery groups in the world and, together with our collaborators, have discovered 21 preclinical development candidates, 13 of which have been progressed to clinical evaluation, many with our partners in the ICR/Royal Marsden Drug Development Unit. Our drug abiraterone (Zytiga) has been approved in the US, Canada and Europe for late-stage prostate cancer. The CCDD's mission is to develop personalised medicines by translating information from the cancer genome and cancer biology into drugs for patient benefit. We implement innovative drug discovery technologies, discover novel mechanism-based drugs, and develop these as rapidly as possible from the laboratory through to hypothesis-testing early clinical trials. We publish our work extensively and have a large network of collaborations with academia, biotechnology companies, and the pharmaceutical industry. Our teams are dedicated to the discovery of small molecule drug candidates, and to the development of high-quality chemical probes to enable new cancer biology research. The Division of Cancer Therapeutics is based in state-of-the art laboratories in the Centre for Cancer Drug Discovery building, opened in 2020 on the ICR Sutton campus. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For further information, please contact Dr Fiona Dziegiel ( ) About The Institute of Cancer Research Why work for us? As a member of staff, you'll have exclusive access to a range of staff benefits . The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information. The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here. At the Institute of Cancer Research, we champion diversity as we believe it fuels innovation and drives impactful research. We welcome applicants from all walks of life, valuing diverse perspectives that enrich our work. Don't let a checklist of qualifications hold you back - if you're passionate about the role, we want to hear from you. Your unique experiences and backgrounds contribute to the richness of our team. We are committed to being an equal opportunity for all, regardless of ethnicity, gender, age, sexual orientation, disability, or any other dimension of diversity. Join us in creating an inclusive environment where everyone's voice is heard and valued.
The Institute of Cancer Research
Sutton, Surrey
External Advertising End Date: Advertising End Date: Salary: £39,805 - £41,900 per annum. Commencement on the salary range is subject tocomparableskills and experience. Hours per week: 35 hours per week (Full Time) Location: Sutton Closing Date: 16th March 2026 Under the guidance of Alexis De Haven Brandon, we are seeking to recruit a Higher Scientific Officer. We seek an experienced and dedicated in vivo scientist. The central aim of this position is to undertake in vivo technical work, playing a key role in supporting a variety of in vivo experiments and laboratory approaches. You will be a highly skilled in vivo scientist with sound knowledge and experience in in vivo approaches in a research setting. You will possess a Home Office Personal Licence. Your responsibilities will include planning and performing animal procedures, maintaining detailed records, and performing some routine laboratory tasks. This position offers an excellent opportunity for a highly skilled in vivo scientist with a passion for in vivo science, and animal welfare. There will occasionally be the need for out of hours work to ensure Home Office compliance, and the needs of the projects are met. The successful candidate will be a motivated individual with a strong background in in vivo techniques. We highly value diversity and encourage candidates from all backgrounds to apply. About you The successful candidate must have: Personal Home Office Licence PIL A,B,C BSc in life sciences or equivalent Proven experience in a technical in vivo research setting - to include techniques such as dosing, surgical and sampling Ability to plan and execute complex in vivo studies, to the highest ethical standards Ability to work independently and collaboratively Department/Directorate Information The In Vivo Pharmacology team (IVP) provides in vivo support for all projects within the Centre for Cancer Drug Discovery (CCDD). The team carries out critical proof-of principle intervention studies and provides the essential pharmacological assays required to guide target validation in addition to the optimisation and selection of new drug candidates. Importantly, these experiments include the demonstration of drug effects in vivo, biomarker discovery and therapy studies, all of which underpin the drug discovery programs across the portfolio. The IVP works across a wide range of tumour models, including human tumour xenografts models (both cell line- and patient-derived xenografts), genetically engineered mouse models, organoid-based models and preclinical metastatic models. The team has specialised skills to develop and implement novel models, and supporting the design and implementation of studies, whilst complying with increasingly complex Home Office regulations. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Alexis De Haven Brandon: . About The Institute of Cancer Research Why work for us? As a member of staff, you'll have exclusive access to a range of staff benefits . The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information. The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here . We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.
External Advertising End Date: Advertising End Date: Salary: £39,805 - £41,900 per annum. Commencement on the salary range is subject tocomparableskills and experience. Hours per week: 35 hours per week (Full Time) Location: Sutton Closing Date: 16th March 2026 Under the guidance of Alexis De Haven Brandon, we are seeking to recruit a Higher Scientific Officer. We seek an experienced and dedicated in vivo scientist. The central aim of this position is to undertake in vivo technical work, playing a key role in supporting a variety of in vivo experiments and laboratory approaches. You will be a highly skilled in vivo scientist with sound knowledge and experience in in vivo approaches in a research setting. You will possess a Home Office Personal Licence. Your responsibilities will include planning and performing animal procedures, maintaining detailed records, and performing some routine laboratory tasks. This position offers an excellent opportunity for a highly skilled in vivo scientist with a passion for in vivo science, and animal welfare. There will occasionally be the need for out of hours work to ensure Home Office compliance, and the needs of the projects are met. The successful candidate will be a motivated individual with a strong background in in vivo techniques. We highly value diversity and encourage candidates from all backgrounds to apply. About you The successful candidate must have: Personal Home Office Licence PIL A,B,C BSc in life sciences or equivalent Proven experience in a technical in vivo research setting - to include techniques such as dosing, surgical and sampling Ability to plan and execute complex in vivo studies, to the highest ethical standards Ability to work independently and collaboratively Department/Directorate Information The In Vivo Pharmacology team (IVP) provides in vivo support for all projects within the Centre for Cancer Drug Discovery (CCDD). The team carries out critical proof-of principle intervention studies and provides the essential pharmacological assays required to guide target validation in addition to the optimisation and selection of new drug candidates. Importantly, these experiments include the demonstration of drug effects in vivo, biomarker discovery and therapy studies, all of which underpin the drug discovery programs across the portfolio. The IVP works across a wide range of tumour models, including human tumour xenografts models (both cell line- and patient-derived xenografts), genetically engineered mouse models, organoid-based models and preclinical metastatic models. The team has specialised skills to develop and implement novel models, and supporting the design and implementation of studies, whilst complying with increasingly complex Home Office regulations. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Alexis De Haven Brandon: . About The Institute of Cancer Research Why work for us? As a member of staff, you'll have exclusive access to a range of staff benefits . The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information. The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here . We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.
